Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Chronic genotype 1-4 HCV infection
For Cohorts 1-9, HCV RNA ≥ 100,000 IU/mL at screening (no HCV RNA restriction for Cohort 10)
Screening laboratory values within defined thresholds
Use of two effective contraception methods if female of childbearing potential or sexually active male
You may not be if
Pregnant or nursing female or male with pregnant female partner
Presence of cirrhosis
Prior exposure to approved or experimental HCV Protease Inhibitors
Co-infection with HIV or hepatitis B virus (HBV)
Current or prior history of clinical hepatic decompensation
Chronic use of systemic immunosuppressive agents
History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol
Clareo Health | Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Voxilaprevir in Adults With Chronic Hepatitis C Virus Infection
